Respi DART 2020 Electronic Poster Session

  • Welcome to the e-poster portal for Respi DART 2020. All accepted abstracts are listed below for your viewing.

  • Please click on each abstract title to review the poster presentation which will open in a pop-up window.

  • If you have any questions regarding the presented data, please use the contact information provided for each presenting author to contact them.

 
 

Peginterferon-lambda for the treatment of COVID-19 in outpatients

Poster Number: 1702 (Oral presentation)

  • Category: Respi DART

  • Abstract

  • Presenter: Jordan Feld, Toronto Centre for Liver Disease, University of Toronto, Canada

  • Contact: jordan.feld@uhn.ca

Broad-spectrum therapeutics against SARS-CoV-2 3CL protease

Poster Number: 1703 (Oral presentation)

Efficacy of sofosbuvir/daclatasvir in moderate and severe COVID-19 infection: the DISCOVER trial.

Poster Number: 1704

  • Category: Respi DART

  • Abstract

  • Presenter: Shahin Merat, Digestive Diseases Research Institute,Tehran University of Medical Sciences, Iran

  • Contact: merat@tums.ac.ir

Performance of serum apolipoprotein-A1 as a sentinel of Covid-19

Poster Number: 1705

  • Category: Respi DART

  • Abstract

  • Presenter: Thierry Poynard, Assistance Publique-Hôpitaux de Paris (AP-HP). Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Institute of Cardiometabolism and Nutrition (ICAN), Paris, France

  • Contact: thierry@poynard.com

Structure-based discovery of potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitors using a multiplex screening platform

Poster Number: 1706 (Oral presentation)

Coronavirus disease 2019 in HIV-infected Solid Organ Transplant Recipients: A Case Series

Poster Number: 1707

Safety of IL-17A blockade with secukinumab in Covid-19 hospitalized patients – interim data from the BISHOP study.

Poster Number: 1708

The in vitro antiviral activity of the anti-hepatitis C virus drugs daclatasvir and sofosbuvir against SARS-CoV-2

Poster Number: 1709 (Oral presentation)

Factors Associated with Readmission Following COVID-19 Hospitalization

Poster Number: 1710 (Oral presentation)

Costs versus prices for new re-purposed drugs to treat COVID-19 infection

Poster Number: 1711

How can we accelerate randomised trials of COVID-19 vaccines and preventative treatments?

Poster Number: 1712

  • Category: Respi DART

  • Abstract

  • Presenter: Hannah Wentzel, Imperial College London, United Kingdom

  • Contact: hbw19@ic.ac.uk